Related Experiment Video
Updated: Aug 14, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular
Y Ozkul1, C Evereklioglu, M Borlu
1Sivas Cad Cebeci Apt A-Blok, 175/15, TR-38020, Kayseri, Turkey.
Insights
The MTHFR C677T gene polymorphism is linked to elevated homocysteine (Hcy) in Behçet's disease (BD) patients. This genetic variation significantly increases the risk of ocular involvement in BD patients.
Area of Science:
- Genetics
- Internal Medicine
- Ophthalmology
Background:
- Elevated homocysteine (Hcy) levels are observed in Behçet's disease (BD) patients, correlating with vascular and ocular complications.
- Genetic factors, such as the 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism, influence Hcy metabolism and can lead to hyperhomocysteinemia.
Purpose of the Study:
- To investigate the potential genetic contribution to elevated plasma Hcy in BD patients.
- To examine the association between the MTHFR C677T polymorphism and ocular involvement in BD.
Main Methods:
- Genotyping for MTHFR C677T polymorphism using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
- Comparison of MTHFR C677T genotype frequencies between 59 BD patients and 42 healthy controls.
- Analysis of the association between MTHFR C677T polymorphism and ocular involvement in BD patients.
Main Results:
- The TT homozygous genotype of the MTHFR gene was more prevalent in BD patients than in controls (11.9% vs 2.4%), though not statistically significant (p=0.063).
- BD patients with ocular involvement showed a significantly higher frequency of the MTHFR TT genotype (27.8%) compared to those without ocular involvement (4.9%, p=0.022) and controls (2.4%, p=0.003).
- The TT homozygous genotype was associated with an increased risk of ocular involvement in BD patients (OR=7.5 compared to BD without ocular involvement, OR=20.0 compared to controls).
Conclusions:
- The C677T polymorphism of the MTHFR gene may contribute to elevated serum Hcy levels in BD patients, particularly those with the TT genotype.
- While no link was found with oral aphthae or genital ulcers, the MTHFR C677T polymorphism is associated with an increased risk of ocular involvement in BD.
- These findings suggest genetic susceptibility and may support the initiation of Hcy-lowering therapy in at-risk BD patients.
Background:
Increased serum levels of homocysteine (Hcy) have been reported in patients with Behçet's disease (BD) with an established risk factor for vascular involvement. Recently, the authors demonstrated that elevated Hcy levels are associated with ocular involvement in such patients. On the other hand, elevated levels of Hcy can result from genetic errors. Indeed, a mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) gene influences Hcy metabolism and, therefore, MTHFR C677T polymorphism provokes hyperhomocysteinaemia.
Aim:
To investigate the possible genetic factor for the elevation of plasma Hcy level in patients with BD by examining gene interaction with the MTHFR C677T polymorphism, a crucial factor of the Hcy metabolism. In addition, the authors aimed to evaluate if there is an association between the C677T polymorphism and the presence of ocular involvement in such patients.
Method:
A total of 59 patients with BD (25 men, 34 women) with a mean age of 34.9 years and 42 age and sex matched healthy control subjects (19 men, 23 women; mean age 32.2) were included in this investigation. MTHFR gene polymorphism was investigated by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) of a genomic DNA fragment at nucleotide 677 in all subjects in both groups. The genetic equilibrium is assumed for the gene frequencies of the MTHFR polymorphism in both samples.
Results:
The genotype of the MTHFR gene differed between the Behçet's patients and control subjects (TT: 11.9 v 2.4%; CT: 55.9 v 61.9%; CC: 32.2 v 35.7 %). TT homozygous genotype was more frequently in BD patients than the controls, though the difference was not significant (p = 0.063). In BD patients with ocular involvement, however, the frequencies of MTHFR TT homogenetic type (27.8%) were significantly and statistically higher than those in BD patients without ocular involvement (4.9%, p = 0.022, odds ratio = 7.5), or the controls (2.4%, p = 0.003, odds ratio = 20.0). TT homozygous genotype was associated with an increased risk for ocular involvement.
Conclusion:
Elevated serum levels of Hcy seem to be a result of C677T polymorphism of the MTHFR gene, with increased TT individuals over CC and CT genotype BD patients. Although no association was shown between the MTHFR reductase C677T polymorphism and the increased risk of oral aphtahe or genital ulcers, a mutation in this gene was associated with an increased risk of ocular involvement, suggesting genetic instability with a potential initiation of Hcy lowering therapy in this patient group.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic Lingo
